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Background: The 39,XY*O mouse, which lacks the orthologues of the ADHD and autism candidate genes STS
(steroid sulphatase) and ASMT (acetylserotonin O-methyltransferase), exhibits behavioural phenotypes relevant to
developmental disorders. The neurobiology underlying these phenotypes is unclear, although there is evidence for
serotonergic abnormalities in the striatum and hippocampus.
Methods: Using microarray and quantitative gene expression analyses, and gas chromatography–mass
spectrometry, we compared brain gene expression and steroid biochemistry in wildtype (40,XY) and 39,XY*O adult
mice to identify non-obvious genetic and endocrine candidates for between-group differences in behaviour and
neurochemistry. We also tested whether acute STS inhibition by COUMATE in wildtype (40,XY) adult male mice
recapitulated any significant gene expression or biochemical findings from the genetic comparison. Data were
analysed by unpaired t-test or Mann Whitney U-test depending on normality, with a single factor of KARYOTYPE.
Results: Microarray analysis indicated seven robust gene expression differences between the two groups (Vmn2r86,
Sfi1, Pisd-ps1, Tagap1, C1qc, Metap1d, Erdr1); Erdr1 and C1qc expression was significantly reduced in the 39,XY*O
striatum and hippocampus, whilst the expression of Dhcr7 (encoding 7-dehydrocholesterol reductase, a modulator
of serotonin system development), was only reduced in the 39,XY*O hippocampus. None of the confirmed gene
expression changes could be recapitulated by COUMATE administration. We detected ten free, and two sulphated
steroids in 40,XY and 39,XY*O brain; surprisingly, the concentrations of all of these were equivalent between groups.
Conclusions: Our data demonstrate that the mutation in 39,XY*O mice: i) directly disrupts expression of the
adjacent Erdr1 gene, ii) induces a remarkably limited suite of downstream gene expression changes
developmentally, with several of relevance to associated neurobehavioural phenotypes and iii) does not elicit large
changes in brain steroid biochemistry. It is possible that individuals with STS/ASMT deficiency exhibit a similarly
specific pattern of gene expression changes to the 39,XY*O mouse, and that these contribute towards their
abnormal neurobiology. Future work may focus on whether complement pathway function, mitochondrial
metabolism and cholesterol biosynthesis pathways are perturbed in such subjects.
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Autism spectrum disorders (ASDs) and Attention Deficit
Hyperactivity Disorder (ADHD) exhibit partially overlap-
ping neurobehavioural symptoms, frequent comorbid-
ity, altered monoaminergic function, and shared genetic
aetiology [1]. Both types of disorder are significantly more
frequently diagnosed in males than in females, suggesting
a potential role for sex-linked genetic risk variants [2], and
both can have long-term adverse consequences for ex-
ample, increased risk for alcohol dependence in ADHD
[3] or lack of independence, close social ties and employ-
ment in ASDs [4].
Both cytogenetic deletions at Xp22.32 encompassing
the X-linked STS gene (encoding the enzyme steroid sul-
phatase) and its immediate neighbours, and inactivating
point mutations within STS, appear to predispose to
ADHD (particularly the inattentive subtype) [5]; larger
cytogenetic deletions encompassing STS and more distant
contiguous genes (notably NLGN4X) seem to predispose
to autism and related disorders [5]. Polymorphisms within
STS are associated with ADHD risk [6,7] and cognitive
function in individuals with ADHD [8], whilst the gene is
expressed in regions of the developing brain whose struc-
ture is known to be altered in ADHD cases [8]. Steroid
sulphatase cleaves sulphate groups from a variety of ster-
oid hormones (for example, dehydroepiandrosterone
sulphate, DHEAS) thereby altering their activity and/or
specificity, and subsequent developmental and physio-
logical effects [9]. As sulphated and non-sulphated steroid
hormones can act as modulators at key neurotransmitter
receptors, including N-methyl-D-aspartic acid (NMDA)
and γ-aminobutyric acid type A (GABAA) receptors [9],
lack of STS developmentally could potentially elicit im-
portant effects on neuronal organisation processes medi-
ated by these neurotransmitters [10].
Inactivating mutations within the ASMT gene, located
within the pseudoautosomal region of the human X
chromosome and encoding the enzyme acetylserotonin
O-methyltransferase that catalyses the final step in mela-
tonin biosynthesis, have been suggested as being potentially
pathogenic in a variety of psychiatric and developmental
conditions, including ASDs [11-17]. Such mutations may
act to reduce systemic melatonin levels, a reported feature
of individuals with ASDs [15]. Alternatively, or additionally,
they could affect upstream substrate levels in the brain or
blood platelets, for example, of the growth factor serotonin
(5-hydroxytryptamine, 5-HT) or blood cell function [15];
elevated platelet serotonin levels are a consistent finding in
ASD cases [18].
The 39,XY*O mouse lacks both the pseudoautosomal
Sts and Asmt genes (and hence their expression in all
tissues) as a consequence of an end-to-end fusion of the
X and Y chromosomes [19]; as such, it has some degree
of construct validity as a genetic mouse model forneurodevelopmental disorders. On an MF1 outbred al-
bino strain background, this mouse also exhibits consid-
erable face validity for such disorders: it is inattentive
[20], hyperactive, emotionally hyper-reactive (showing in-
creased indices of stress in novel or arousing environments),
occasionally aggressive [21], and perseverative (showing
persistent responding in the absence of reinforcement)
[19,22] and exhibits reduced systemic DHEA levels [21].
Whilst melatonin levels in wildtype and 39,XY*O MF1
male mice remain to be determined, other outbred albino
strains are known to produce significant quantities of the
hormone [23].
Currently, the neurobiology of the 39,XY*O mouse is
poorly defined, although we have previously shown that
it exhibits altered monoaminergic chemistry, notably ele-
vated hippocampal and striatal serotonin levels and reduced
5-HT turnover in these regions [19,22]. Interestingly, how-
ever, the 39,XY*O mouse, in contrast to individuals with
ADHD, exhibits enhanced behavioural inhibition relative to
40,XY male controls as indexed by performance on murine
versions of the 5-choice Serial Reaction Time Task and the
Stop Signal Reaction Time Task [20, S.T., O.A.O. and W.D.,
unpublished observations]. We have previously shown that
acute administration of one dose of the specific steroid sul-
phatase inhibitor COUMATE to wildtype male mice also
results in inattention [20] and enhanced behavioural inhib-
ition [S.T., O.A.O. and W.D., unpublished observations],
suggesting that these phenotypes in the 39,XY*O mouse are
due to the ongoing activity of the enzyme. Other pheno-
types in the 39,XY*O mouse (for example, hyperactivity and
anxiety) cannot be recapitulated by acute inhibition of ster-
oid sulphatase [21], suggesting that they may arise from the
developmental effects of deficiency for the enzyme, or alter-
natively from neuroendocrinological abnormalities as a
consequence of ASMT deficiency.
Here, we further investigated the neurobiology of the
39,XY*O mouse using two methods, with a view to iden-
tifying biological correlates of the behaviours mentioned
above. First, we compared gene expression in adult 40,
XY and 39,XY*O whole brain tissue by microarray to
identify non-obvious genetic changes between the two
groups, that is changes that could not be predicted a
priori on the basis of known biology; we assayed whole
brain tissue given that Sts is widely expressed through-
out the mouse brain, and because disruptions to mul-
tiple brain regions were likely to underpin the 39,XY*O
behavioural phenotypes. We also tested to see whether
any of the significant changes were seen in the 39,XY*O
hippocampus or striatum (given the known changes in
5-HT levels), or in COUMATE-treated male mouse
whole brain (and hence whether they could explain the
effects of acute STS deficiency on attention and behav-
ioural inhibition). Second, we characterised brain ste-
roids in the adult 40,XY mouse for the first time, and
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anticipated that these combined approaches might reveal
new pathophysiological mechanisms underlying pheno-
types associated with STS/ASMT deficiency specifically
and neurodevelopmental disorders more generally, and
might highlight novel factors protecting against behav-
ioural disinhibition. We report that 39,XY*O mice show
a highly specific pattern of gene expression changes,
with several being of relevance to developmental disor-
ders, but surprisingly, no large changes in brain steroid
levels.
Methods
Subjects
All experimental research involving animals was performed
in accordance with the Animal (Scientific Procedures)
Act 1986 (United Kingdom) and was approved by the
UK Home Office. 39,XY*O and 40,XY mice, matched
for genetic background (predominantly MF1 strain), were
bred and genotyped for the presence or absence of Sts
at the Medical Research Council National Institute for
Medical Research (MRC NIMR) as described previously
[22]; at six weeks of age, behaviourally naïve, group-housed
40,XY (n = 10) and 39,XY*O (n = 10) mice were culled by
cervical dislocation between 1200 and 1500 hours, and
their brains frozen immediately at −80°C for subse-
quent RNA extraction. Some 40,XY and 39,XY*O mice
were subsequently transferred to Cardiff University, where
they were treated with antibiotics to treat a Pasteurella
pneumotropica infection prior to release onto the open
racks and behavioural testing; these mice were then
culled by cervical dislocation between 1100 and 1300
hours (aged 10 to 12 months), and their hippocampi and
striata dissected from the left hemisphere and frozen im-
mediately at −80°C (n = 6 per group). For the pharmaco-
logical study, behaviourally naïve, six-week old, male MF1
mice (Harlan, UK) were administered 7-O-sulphamoyl-4-
methylcoumarin (COUMATE) at a dose previously shown
to influence behaviour [20] (10 mg/kg in 0.5% methylcel-
lulose 0.9% saline vehicle, per os (po), n = 12) or vehicle
alone (n = 12); 24 hours later they were culled by cervical
dislocation between 1600 and 1830 hours, their brains dis-
sected and immediately frozen at −80°C. For the brain
steroid measurements, behaviourally-naïve, group-housed
mice (n = 8 per group) from MRC NIMR were culled by
cervical dislocation between 1100 and 1500 hours (aged
five to seven months), their brains dissected and frozen
immediately at −80°C.
RNA extraction and cDNA biosynthesis
High quality total RNA (absorbance ratios of 1.7 to 2.1)
for the microarray study was extracted from 40,XY and
39,XY*O hemibrain tissue using RNeasy Lipid Tissue Kit
(Qiagen, Manchester, UK), and DNase-treated usingRNase-free DNase kit (Qiagen, Manchester, UK). For
other tissue samples, high quality RNA was extracted by
homogenising the tissue in TRIReagent (Sigma-Aldrich,
Gillingham, UK), precipitating with isopropanol, washing
in 75% ethanol, and resuspending in RNase-free distilled
water; DNase treatment was then carried out using the
TURBO DNA-free kit (Life Technologies, Paisley, UK).
cDNA was synthesised from 1 to 2 μg RNA per sample
using EcoDry Premix with random hexamers (Clontech,
Mountain View, CA, USA), and diluted 25-fold.
Microarray analysis
Total RNA was supplied to Source Bioscience Ltd.
(Nottingham, UK) where it underwent quality control
checks prior to conversion to cRNA and hybridisation
to the Mouse Gene 1.0 ST array (Affymetrix, Santa Clara,
USA) according to their standard protocol. To reduce the
possibility of spurious expression differences, we carried
out four separate hybridisations: 40,XY1 (five pooled
hemibrains), 40,XY2 (five pooled hemibrains), 39,XY*O1
(five pooled hemibrains), and 39,XY*O2 (five pooled hemi-
brains). Array data were subject to normalisation using the
Robust Multipoint Average (RMA) procedure (background
adjustment, quantile normalisation and summarisation)
within the Affymetrix Expression Console prior to being
loaded in the CLC Bio Genomics Workbench to examine
differential expression across samples. Microarray data
are available via ArrayExpress [24] (accession number
E-MEXP-3943).
Quantitative polymerase chain (qPCR) analysis
Quantitative PCR (qPCR) analysis of gene expression
was performed using a Rotorgene 6000 coupled with a
CAS1200 automated set-up, and utilizing standard con-
sumables (Qiagen, Manchester, UK). PCR reactions were
performed using 5 μl cDNA mix and 200 nM custom-
designed primers (Additional file 1) and Quantace SensiMix
(Bioline, London, UK). qPCR data were analysed using ΔCt
methods as described previously [25]. Briefly, individual
PCR reaction data were normalised to the mean of at least
three ‘housekeeping gene standards’ (Hprt, Gapdh, Actb
and Rn18s, whose expression was significantly correlated
within the samples), giving a value known as ΔCt. The data
were processed further to show how the 39,XY*O values vary
with respect to those of the 40,XY (ΔΔCt) and allow simpler
graphical representation after transformation (2−ΔΔCt).
Brain steroid analysis
Pooled samples (40,XY: n = 4, 39,XY*O: n = 4) were gen-
erated for each group (two whole brains per pool). Free
steroids and their sulphate esters were extracted from
brain tissue and fractionated prior to derivatisation with
methoxyamine (MO) and trimethylsilylimidazole (TMSI)
for gas chromatography-mass spectrometry (GC-MS) as
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were deconjugated by incubation with Helix sulphatase
rather than by solvolysis [27]. Briefly, after drying down
and redissolving in sodium acetate (0.5 M, pH 5.0), the
sulphates were deconjugated by incubation with the aryl-
sulphatase enzyme from Helix pomatia Type H1 (Sigma-
Aldrich, Gillingham, UK) at 1 mg/ml overnight at 40°C,
then at 55°C for two hours. The deconjugated steroids
could then be recovered by loading the incubate onto a
60 mg hydrophobic-lipophilic balance (HLB) cartridge
(Waters, Milford, MA, USA). After a wash with 5 ml
water, the steroids were eluted from this cartridge with 4
ml ethyl acetate. These steroids liberated by deconjuga-
tion of the sulphate fraction were then dried down under
nitrogen and derivatised with MO and TMSI for GC-
MS alongside the steroids from the free steroid fraction
of mouse brain. Increasing amounts (1.4 to 23.1 ng) of
standard reference steroids were derivatised at the same
time for calibration and each sample and calibration ref-
erence included a fixed amount (50 ng) of the internal
standards 16-dehydropregnenolone and 6α-methyl-17-
hydroxyprogesterone. Column conditions for the GC were
as previously described, with elution of the MO-TMS-
steroids detected by selective ion monitoring as follows:
androsterone, 270 and 360; dehydroepiandrosterone, 268
and 358; epiandrosterone, 270 and 360; androstenediol,
129 and 239; 17β-oestradiol, 129, 285 and 416; testos-
terone, 129 and 389; allopregnanolone, 298 and 388;
16-dehydropregnenolone, 400 and 415; allopregnane-
diol, 269 and 346; pregnenolone, 288 and 386; epial-
lopregnanolone, 243 and 388; 5α-dihydroprogesterone,
288 and 343; 20β-dihydropregnenolone, 372 and 462;
20α-dihydropregnenolone, 372 and 462; progesterone,
341 and 372; 5α,20α-tetrahydroprogesterone, 289 and
303; 6α-methyl-17-hydroxyprogesterone, 443 and 474.
Statistics
For the microarray data, statistical significance of the
changes in mean expression levels per group was exam-
ined by the unpaired two-tailed t-test with a single over-
all factor of KARYOTYPE (that is 40,XY or 39,XY*O)
within CLC Bio Genomics Workbench; P-values taking
into account correction for False Discovery Rate were
also calculated. For the qPCR analyses, samples > two
standard deviations from the group mean were excluded
as outliers; statistical significance of the changes in expres-
sion levels was examined using 2-ΔCt values by the unpaired
t-test (normally distributed data according to Shapiro-
Wilks test) or Mann-Whitney U-test (non-normally distrib-
uted data according to Shapiro-Wilks test) with a single
factor of KARYOTYPE. Where variance within the two
groups was unequal, Greenhouse-Geisser corrected de-
grees of freedom are indicated. Where the direction of ef-
fects could be predicted, that is in confirming microarrayfindings, a one-tailed test was used; in other cases, a two-
tailed test was used. For the brain steroid hormone
analyses, data were tested for normality as above, and
analysed by the unpaired t-test with a single factor of
KARYOTYPE. P-values ≤ 0.05 were regarded as signifi-
cant, and all data are presented as mean values ± standard
error of the mean.
Results
Microarray analysis
Filtering for nominal P-values < 0.05, and >2-fold change
identified just 13 genes of interest in addition to Sts,
which was, as expected, found to be significantly
downregulated; of these genes, eight appeared to be
upregulated, and five downregulated (Table 1). Asmt
was not represented on the array. Just one gene, Erdr1
(NM_133362.1) survived correction for False Discovery
Rate (P = 0.044). Of particular note was the finding that
two genes that lie adjacent to one another on chromo-
some 11 (Sfi1 and Pisd-ps1) were both upregulated, a re-
sult highly unlikely to occur by chance. A further 1,536
transcripts (out of 26,166 RefSeq transcripts represented
on the array) were potentially more subtly differentially
expressed (that is P < 0.05, but <2-fold expression change);
of these, 47 had previously been implicated in autism and/
or ADHD according to relevant online databases [28-30]:
Abat, Arhgap15, Cdh8, Chrna7, Cldn5, Cntn3, Crygc,
Cttnbp2, Ctnna2, Dctn5, Dhcr7, Dhrs3, Ehmt1, Elovl6,
Eif4e1b, Eln, Fbxo40, Gclc, Gdi1, Gfod1, Gpd2, Grid2,
Hepacam, Hes1, Hes6, Irak1, Kcnj10, Lphn3, Lrp2, Lrrn3,
Mcph1, Mctp1, Mid1, Nlgn1, Npy5r, Nucb1, Park2, Pdzd4,
Plcb1, Prodh, Prrt2, Prune2, Scn2a1, Slc25a12, Srsf3,
Syngap1 and Ythdc2.
Confirmation of microarray results by quantitative PCR
(qPCR)
Initially, we sought to confirm microarray changes > 2-
fold and with a P-value < 0.05 by qPCR using individual
samples (n = 10 per group). The direction of effect was
consistent between the microarray and the qPCR ana-
lysis for 12 of the 13 genes in Table 1. However, the
expression of only seven of the 13 genes was con-
firmed as being significantly different between the two ex-
perimental groups by qPCR (Figure 1A): six upregulated:
Vmn2r86: t8.00 = −6.11, P < 0.001 (expression higher than
40,XY mean in 10/10 39,XY*O samples), Sfi1: t16 = −8.62,
P < 0.001 (expression higher than 40,XY mean in 10/10
39,XY*O samples), Pisd-ps1: t11.84 = −1.84, P < 0.05
(expression higher than 40,XY mean in 7/10 39,XY*O
samples), Tagap1: t17 = −3.32, P < 0.005 (expression
higher than 40,XY mean in 8/10 39,XY*O samples),
C1qc: t9.07 = −11.47, P < 0.001 (expression higher
than 40,XY mean in 10/10 39,XY*O samples), Metap1d:
t9.29 = −12.02, P < 0.001 (expression higher than 40,XY
Table 1 Genes showing >2fold change at P < 0.05 in 39,XY*O whole brain based on the microarray analysis
Upregulated in 39,XY*O brain
Gene Chromosome Product Fold change P-value Human orthologue
Gm16432 1 Function unknown 5.5 0.006 None
Vmn2r86 10 Vomeronasal 2 receptor 86 3.6 0.03 None
Sfi1 11 Sfi1 homolog, spindle assembly associated (yeast) 3.3 0.007 SFI1 (22q12.2)
Pisd-ps1 11 Phosphatidylserine decarboxylase, pseudogene 1 2.7 0.02 None
Tagap1 17 T cell activation GTPase activating protein 1 2.4 0.01 None
C1qc 4 Complement component 1, q subcomponent, C chain 2.3 0.002 C1QC (1p36.11)
Fam177a 12 Family with sequence similarity 177, member A 2.2 0.004 FAM177A1 (14q13.2)
Metap1d 2 Methionyl aminopeptidase type 1D 2.0 0.0003 METAP1D (2q31.1)
Downregulated in 39,XY*O brain
Gene Chromosome Product Fold change p-value Human orthologue
Erdr1 Y Erythroid differentiation regulator 1 3.6 1.3x10−6 None
Trdn 10 Triadin 3.1 0.03 TRDN (6q22.31)
Gm12696 4 Pseudogenic RNA 2.9 0.01 None
Fut11 14 Fucosyltransferase 11 2.2 0.002 FUT11 (10q22.2)
AA388235 17 Non-coding RNA 2.1 0.03 None
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Erdr1: t9.00 = 5.96, P < 0.001 (expression lower than 40,XY
mean in 10/10 39,XY*O samples). Prima facie, these genes
do not appear to function within common known path-
ways, being involved in signal transduction (Vmn2r86),
phosphatase activity regulation (Sfi1), complement ac-
tivation in the immune response (C1qc), mitochondrial
proteolysis (Metap1d) and regulation of cell proliferation
and migration (Erdr1) [31]. The expression of Fam177a
showed a trend towards being more highly expressed in
39,XY*O brain than 40,XY brain (t17 = −1.51, P = 0.08).
The expression of the Gm16432, Trdn, Gm12696, Fut11
and AA388235 genes did not differ significantly as a func-
tion of KARYOTYPE (t18 = −0.67, P = 0.26, t18 = 0.45, P =Vm
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(B). *P < 0.05, **P < 0.01, ***P < 0.001.0.33, t18 = −0.18, P = 0.43, t17 = 1.08, P = 0.15 and P =
0.94 respectively).
The Erdr1 gene is located adjacent to the fusion point
of the X and Y chromosomes in the 39,XY*O mouse;
therefore we tested whether two additional genes not
represented on the microarray, which lie directly adja-
cent to Erdr1 (G530011O06Rik and LOC100861696) [19]
were also differentially expressed in 39,XY*O and 40,XY
brain; this did not appear to be the case: G530011O06Rik:
t13.4 = −0.037, P = 0.97, LOC100861696: P = 0.33 (see
Additional file 2).
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the 11 genes examined, none were confirmed as being
significantly differentially expressed between 40,XY
and 39,XY*O groups (Figure 1B, Chrna7: t17 = −0.15,
P = 0.44, Abat: P = 0.33, Grm1: t17 = 1.26, P = 0.12,
Lrrn3: t18 = 0.77, P = 0.23, Ppp2r5c: t17 = −0.62, P =
0.28, Ercc4: t18 = 0.32, P = 0.38, Plcb1: t16 = 0.41, P = 0.34,
Ctnna2: t17 = 1.71, P = 0.06, Dhcr7: t18 = 1.04, P = 0.16,
Nrg3: t18 = −0.15, P = 0.45, Plekhb1 t18 = −0.27, P = 0.40).
Gene expression changes in the hippocampus and
striatum of 39,XY*O mice
Of the seven genes whose expression levels differed
in 40,XY and 39,XY*O whole brain tissue, six were
expressed in the adult hippocampus, and all showed
reduced mean levels in 39,XY*O tissue (Figure 2A).
However, for only two of these (Erdr1 and C1qc), was
this reduction statistically significant: Sfi1: t10 = 1.81,
P = 0.10, Pisd-ps1: t10 = 1.20, P = 0.26, Tagap1: t10 =
0.78, P = 0.45, Metap1d: t10 = 1.04, P = 0.33, Erdr1:
t5.00 = 3.17, P = 0.025 (expression lower than 40,XY mean
in 6/6 39,XY*O samples), C1qc: P = 0.004 (expression
lower than 40,XY mean in 6/6 39,XY*O samples)). We also
examined hippocampal expression of Dhcr7 (encoding
7-dehydrocholesterol reductase, P < 0.05 in the micro-
array analysis) given that this gene had previously been
implicated in neurodevelopmental disorders, and that
its deficiency had been implicated in altered seroto-
nergic function [32]. We found that in 39,XY*O hippocam-
pus, Dhcr7 expression was significantly downregulated
relative to 40,XY expression: t5.97 = 3.47, P = 0.013 (expres-
sion lower than 40,XY mean in 6/6 39,XY*O samples)
(Figure 2A).
Of the seven genes whose expression levels differed
in 40,XY and 39,XY*O whole brain tissue, six were
expressed in the adult striatum; we also examinedSf
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Figure 2 Gene expression in 40,XY and 39,XY*O adult brain regions. O
microarray and known to be expressed in the hippocampus, two were sign
C1qc); a third gene, Dhcr7, implicated in serotonergic neurodevelopmental
C1qc were also significantly downregulated in the 39,XY*O striatum (B).*P <Dhcr7 expression in this tissue. Both Erdr1 and C1qc
genes were found to be significantly downregulated in
39,XY*O striatum: t5.19 = 3.12, P = 0.025 and t10 = 8.69,
P < 0.001 respectively (expression lower than 40,XY mean
in 6/6 39,XY*O samples for both genes). The expression
of the remaining five genes was equivalent in 40,XY
and 39,XY*O striatum (Figure 2B, Sfi1: t10 = 1.35, P =
0.21, Pisd-ps1: t10 = −0.58, P = 0.58, Tagap1: t6.59 =
1.29, P = 0.24, Metap1d: t10 = 1.04, P = 0.32, Dhcr7:
t10 = 0.33, P = 0.75).
Brain gene expression changes in wildtype
COUMATE-treated male mice
To determine whether the behavioural effects arising
from acute steroid sulphatase inhibition could be due to
altered expression of the Vmn2r86, Sfi1, Pisd-ps1,
Tagap1, C1qc, or Map1d genes, we compared their ex-
pression in COUMATE and vehicle-treated MF1 male
hemibrain. Erdr1 expression was not examined in
COUMATE-treated brain given that its reduced expres-
sion in the 39,XY*O brain was due to a direct effect of
the genetic mutation and not a downstream effect of Sts
or Asmt deficiency. None of the six genes assayed were
significantly differentially expressed in these tissues:
Vmn2r86 (t22 = −0.99, P = 0.33), Sfi1 (t21 = 0.01, P =
0.99), Pisd-ps1 (t20 = 0.84, P = 0.41), Tagap1 (t22 = −0.82,
P = 0.42), C1qc (t22 = −0.42, P = 0.68), Metap1d (t21 =
0.64, P = 0.53) (Additional file 3).
Steroid hormone analysis
Of the 15 steroids whose identity could reliably be deter-
mined from their elution and ion profile in our GC-MS
analyses, ten had concentrations above the limit of de-
tection in the free steroid fraction: (dehydroepiandrosterone
(DHEA), epiandrosterone, testosterone, allopregnanolone,
pregnenolone, epiallopregnanolone, 5α-dihydroprogesterone,Sf
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tetrahydroprogesterone). The concentrations of these
ten steroids did not differ significantly between 40,XY
and 39,XY*O brains, although there was considerable
intra-group variability, particularly in the mutant
group (Table 2).
In the steroid sulphate fraction, two steroids had con-
centrations above the limit of detection (DHEAS and
epiandrosterone sulphate); the concentrations of both of
these steroids did not differ significantly in 40,XY and
39,XY*O brain (Table 2).
Discussion
The 39,XY*O mouse model exhibits face and construct
validity for neurodevelopmental disorders, showing be-
havioural endophenotypes associated with such condi-
tions, and lacking two genes (Sts and Asmt) whose
human orthologues have been implicated in ADHD andTable 2 Levels of free and sulphated steroids in whole adult
Steroid
(systematic name in brackets)
Free steroids
40,XY
Concentration
(ng/g)
39,XY*O
Concentration
(ng/g)
S
Androsterone
(5α-androstan-3α-ol-17-one)
ND; < 4.56 ND; < 4.56
dehydroepiandrosterone
(5-androsten-3β-ol-17-one)
36.15 ± 9.74 32.91 ± 15.21
Epiandrosterone
(5α-androstan-3β-ol-17-one)
2.80 ± 0.12 3.60 ± 0.44 −
Androstenediol
(5-androsten-3β,17β-diol)
ND; < 0.01 ND; < 0.01
17β-oestradiol
(1,3,5(10)-oestratrien-3,17β-diol)
ND; < 0.53 ND; < 0.53
Testosterone
(4-androsten-17β-ol-3-one)
19.64 ± 2.27 19.63 ± 9.81
Allopregnanolone
(5α-pregnan-3α-ol-20-one)
1.47 ± 0.27 1.95 ± 0.77 −
Allopregnanediol
(5α-pregnan-3α,20α-diol)
ND; < 0.01 ND; < 0.01
Pregnenolone
(5-pregnen-3β-ol-20-one)
31.26 ± 13.37 25.12 ± 15.05
Epiallopregnanolone
(5α-pregnan-3β-ol-20-one)
17.07 ± 5.13 25.25 ± 17.19 −
5α-dihydroprogesterone
(5α-pregnan-3,20-dione)
12.75 ± 5.26 15.01 ± 6.16 −
20β-dihydropregnenolone
(5-pregnen-3β,20β-diol)
ND; < 3.10 ND; < 3.10
20α-dihydropregnenolone
(5-pregnen-3β,20α-diol)
0.91 ± 0.11 0.94 ± 0.09 −
Progesterone
(4-pregnen-3,20-dione)
3.74 ± 0.34 5.84 ± 2.05 −
5α,20α-tetrahydroprogesterone
(5α-pregnan-20α-ol-3-one)
3.71 ± 0.22 3.97 ± 0.48 −
N/A not applicable, ND not detectable.autism pathogenesis respectively. In this study, we inves-
tigated the neurobiology of this model by two methods
with a view to identifying mechanisms by which loss of
function of these genes might contribute towards behav-
ioural pathology; this work is important given the current
lack of availability of single gene knockout models for Sts
and Asmt.
Microarray and quantitative PCR analyses comparing
40,XY and 39,XY*O brain tissue identified a surprisingly
small number of robust gene expression differences be-
tween the groups. Our inability to verify differential
microarray expression calls at P < 0.05 for multiple tran-
scripts of relevance to autism and ADHD suggests that
we are likely to have successfully identified all the genes
that truly differ in their expression across the whole
brain in 40,XY and 39,XY*O mice. However, it is possible
that there are further group differences in gene expres-
sion within specific brain regions; indeed, our40,XY and 39,XY*O mouse brain (n = 4 per group)
Steroid sulphates
ignificance t6
40,XY
Concentration
(ng/g)
39,XY*O
Concentration
(ng/g)
Significance t6
N/A ND; < 0.63 ND; < 0.63 N/A
0.18, P = 0.86 0.51 ± 0.02 0.53 ± 0.01 −1.34, P = 0.23
1.77, P = 0.13 0.71 ± 0.02 0.72 ± 0.01 −0.66, P = 0.54
N/A ND; < 0.45 ND; < 0.45 N/A
N/A ND; < 0.05 ND; < 0.05 N/A
0.00, P = 1.00 ND; < 1.77 ND; < 1.77 N/A
0.59, P = 0.58 ND; < 0.01 ND; < 0.01 N/A
N/A ND; < 0.01 ND; < 0.01 N/A
0.31, P = 0.77 ND; < 0.01 ND; < 0.01 N/A
0.46, P = 0.67 ND; < 0.37 ND; < 0.37 N/A
0.28, P = 0.79 ND; < 0.01 ND; < 0.01 N/A
N/A ND; < 0.01 ND; < 0.01 N/A
0.21, P = 0.84 ND; < 0.01 ND; < 0.01 N/A
1.01, P = 0.35 ND; < 4.41 ND; < 4.41 N/A
0.50, P = 0.64 ND; < 1.61 ND; < 1.61 N/A
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of Htr2c (encoding the serotonin 2c receptor) which we
have previously shown to be upregulated in the 39,XY*O
hippocampus [22].
Erdr1 gene expression was significantly reduced in 39,
XY*O whole brain, and in hippocampal and striatal dis-
sections; this gene is retained in the 39,XY*O mouse and
is located adjacent to the fusion point of the X and Y
chromosomes [19]. Our current results suggest that in
addition to deleting of the Sts and Asmt genes, the le-
sion in 39,XY*O mice disrupts a genetic element that
enhances Erdr1 expression. Theoretically, in concert
with loss of Sts and Asmt, reduced expression of the
widely-expressed, but poorly-characterised, erythroid
differentiation regulator 1 protein encoded by Erdr1
could contribute towards downstream gene expression
changes, abnormal striatal and hippocampal monoamine
neurochemistry, and behavioural phenotypes in the
39,XY*O model; brain and behavioural investigations
in mice in which the function of this gene alone is
disrupted will help clarify the extent and specificity of
this contribution.
Our microarray and qPCR analyses also showed that
the expression of C1qc (encoding the protein comple-
ment component 1, q subcomponent, c chain) was up-
regulated in the brains of young, behaviourally-naïve
39,XY*O mice, but downregulated in the striata and
hippocampi of older, behaviourally-trained mutant an-
imals. These data suggest a potential basis for the neuro-
chemical and behavioural abnormalities seen in the
39,XY*O mouse that may be sensitive to spatiotempo-
ral or environmental regulation, and further suggest
the possibility that the neurobehavioural pathology in
individuals lacking functional STS and/or ASMT proteins
may be due, in part, to altered C1QC levels. Previous
animal and clinical studies have implicated aberrant
expression of C1q family members in developmental
and behavioural phenotypes. In rodents, C1q deletion
results in altered synaptic elimination [33,34], C1qc
expression levels are altered in a model of develop-
mental hippocampal pathology [35], and C1qc expression
is associated with behavioural phenotypes (notably the
consumption of ethanol relative to water) [36]. In
man, individuals with autism can exhibit elevated
C1QC serum levels [37] and altered gastrointestinal
C1q deposition [38,39]. Whether the 39,XY*O mouse
exhibits alterations in synaptic structure/function or
hippocampal structure, or heightened alcohol prefer-
ence remains to be investigated. It also remains to be
seen whether individuals with elevated C1QC levels
and autism possess genetic mutations in either STS
or ASMT, and whether individuals lacking functional
STS and/or ASMT genes are at increased risk of alcohol
dependence.By the same logic, the present findings further indicate
that disrupted expression of Metap1d and/or Sfi1 could
play a role in 39,XY*O phenotypes, and in developmental
phenotypes associated with Xp22.3 mutations, but prob-
ably not through influencing striatal or hippocampal
physiology. There is some evidence for an association
between a linkage block at 2q31.1 containing METAP1D
and autism [40], whilst copy number variants encom-
passing SFI1 have previously been identified in autism
and related developmental disorders [41-45].
We also showed that the genetic mutation in 39,XY*O
mice resulted in reduced hippocampal expression of the
Dhcr7 gene. DHCR7 is a known modulator of serotoner-
gic system development in mammals [32]; therefore, its
reduced expression represents a strong candidate mech-
anism for abnormal serotonin levels in the 39,XY*O
hippocampus and associated behavioural phenotypes
[19,22]. In man, defects in the DHCR7 enzyme underlie
Smith-Lemli-Opitz syndrome (SLOS). Individuals with
SLOS exhibit a range of behavioural symptoms with some
overlap with autism, including: hyperactivity, aggression,
insomnia, self-injurious behaviour, sensory hypersensitiv-
ity and repetitive behaviours [32]; interestingly, several of
these behavioural abnormalities are also observed in the
39,XY*O mouse [19,21,22], indicating that hippocampal
loss of DHCR7 function may underlie key SLOS pheno-
types, and suggesting the 39,XY*O mouse as a potential
novel model for aspects of the syndrome.
Genetic and functional work in mice has indicated a
link between steroid sulphatase and aggressive behaviour
[46,47]. Consistent with this, 39,XY*O mice [21], and
mice co-administered COUMATE and DHEAS [48], ex-
hibit elevated levels of aggression. Previous rodent stud-
ies have demonstrated that major urinary proteins may
elicit aggressive behaviour through their actions at sen-
sory neurons expressing Vmn2r putative pheromone re-
ceptors [49]. Of the 124 genes within the Vmn2r family,
the expression of just one,Vmn2r86, was significantly al-
tered in 39,XY*O brain; this increased expression thus
represents an excellent candidate mechanism underlying
aggression in these mutant mice. The fact that there is
no human orthologue of Vmn2r86 may explain why in-
dividuals with Xp22.3 deletions encompassing STS and/
or ASMT do not consistently show obvious aggressive
tendencies.
Acute administration of COUMATE, a specific steroid
sulphatase inhibitor, given at a dose known to induce be-
havioural changes, did not recapitulate any of the whole
brain gene expression changes seen in the 39,XY*O
mouse. There are two obvious possibilities why this
might be the case: i) the expression changes in the 39,
XY*O mouse result from abnormal developmental ex-
pression of STS and/or ii) the gene expression changes in
the 39,XY*O mouse are the result of loss of function of
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found no effect of acute administration of COUMATE on
the concentrations of endogenous DHEAS or DHEA in
whole mouse brain, although the drug did reduce entry of
systemic DHEAS into the brain [50]. Thus, the molecular
basis of COUMATE-induced behavioural changes remains
obscure; it is plausible that the drug induces brain region-
specific gene expression changes that we were unable to
detect, and this possibility remains to be investigated.
Our current analyses provide, for the first time, a sys-
tematic profile of the steroid milieu in the mouse brain.
There was substantial overlap between the free and
sulphated steroids that were detectable in the adult male
mouse brain (present data), and those that were most
readily detectable in the adult male rat brain [26] consist-
ent with a degree of cross-species homology, although,
interestingly, concentrations of most compounds tended
to be higher in mouse brain. We found no significant dif-
ferences in the concentrations of the detectable com-
pounds between 40,XY and 39,XY*O brains, consistent
with an absence of large between-group differences in
steroid brain biochemistry. This finding, taken together
with our previous data showing reduced serum DHEA
levels in 39,XY*O mice [19] suggests the possibility
that where STS is absent developmentally, as in 39,XY*O
mice, a compensatory mechanism is recruited to cleave
sulphated steroid esters in brain, but not in peripheral tis-
sues. Due to the difficulty of generating 39,XY*O mice and
precisely genetically-matched controls, and the apparent
variability in brain steroid levels in the mutant group, our
study had limited power, with several steroids below the
limit of detection. As such, we cannot completely exclude
the possibility that there are subtle differences in levels of
one or more steroids within 40,XY and 39,XY*O brain
tissue.
Conclusions
Here, we have shown that the genetic mutation in
39,XY*O mice, in addition to deleting the Sts and Asmt
genes, also results in significant downregulation of the ad-
jacent Erdr1 gene. In the absence of Sts or Asmt single
gene knockout mice, the present study gives the first clues
as to possible downstream gene expression changes that
might result from the loss of one (or both) of these genes;
of the limited number of robust resultant gene expression
changes, several may be pertinent to 39,XY*O neurochem-
ical and behavioural phenotypes, and hence, to similar
phenotypes in individuals with loss of function muta-
tions within STS or ASMT. Importantly, it should be
noted that just because gene expression differences
across genotypes are large, they might not necessarily
be biologically significant.
Future functional validation and pathway analysis
studies in the 39,XY*O mouse throughout development,incorporating an examination of the spatiotemporal
dynamics of protein changes indicated by our present
study, should further elucidate the neurobiological
pathways by which the 39,XY*O mutation gives rise to
behavioural phenotypes analogous to those seen in neuro-
developmental disorders. Future work might examine
whether the gene expression changes seen here are reca-
pitulated in accessible tissues from individuals lacking STS
and/or ASMT, and could test for abnormalities in comple-
ment pathway function, mitochondrial metabolism and
cholesterol biosynthesis. Should this be the case, these
physiological abnormalities could modulate either the risk
of developing ADHD or autism, and/or to the clinical
course of these disorders.
Our analyses indicated no large differences in brain
steroid concentration between 40,XY and 39,XY*O adult
mice, and hence, suggest that altered steroid biochemis-
try may not be a significant contributor to abnormal
brain and behavioural phenotypes in this mouse model,
nor to similar phenotypes in individuals with mutations
in STS and/or ASMT. However, a developmental differ-
ence in brain steroid levels between Sts/Asmt-deficient
and wildtype subjects may plausibly exist and contribute
towards between-group adult behavioural phenotypes.
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